Glomerulosclerosis, focal

Clinical trials for Glomerulosclerosis, focal explained in plain language.

Never miss a new study

Get alerted when new Glomerulosclerosis, focal trials appear

Sign up with your email to follow new studies for Glomerulosclerosis, focal, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Mycophenolate vs cyclosporine: the battle to halt kidney damage in FSGS

Disease control Completed

Researchers are testing whether a combination of mycophenolate mofetil and steroids works better than cyclosporine at reducing protein in the urine of people with focal segmental glomerulosclerosis (FSGS), a rare kidney disease. The trial enrolls people aged 2 to 40 with biopsy-c…

Matched conditions: GLOMERULOSCLEROSIS, FOCAL

Phase 3 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control

Last updated Sep 20, 2026 00:00 UTC

Glomerulosclerosis, focal

Get alerted when new Glomerulosclerosis, focal trials appear

Mycophenolate vs cyclosporine: the battle to halt kidney damage in FSGS